Skip to main content

Table 3 Summary of on-therapy treatment-emergent adverse events occurring in ≥10% of patients in either treatment arm (Safety population)

From: Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial

  Asian patients, n (%) Non-Asian patients, n (%)
  Pazopanib
(n = 186)
Sunitinib
(n = 177)
Pazopanib
(n = 348)
Sunitinib
(n = 355)
Preferred Term Any grade Grade 3 Grade 4 Any grade Grade 3 Grade 4 Any grade Grade 3 Grade 4 Any grade Grade 3 Grade 4
Neutropenia 44 (24) 11 (6) 1 (< 1) 77 (44) 25 (14) 5 (3) 15 (4) 4 (1) 1 (< 1) 68 (19) 26 (7) 1 (< 1)
Neutrophil count decreased 27 (15) 2 (1) 2 (1) 47 (27) 17 (10) 0 1 (< 1) 0 0 14 (4) 7 (2) 0
Neutropenia/neutrophil count decreaseda 71 (38) 13 (7) 3 (2) 124 (70) 42 (24) 5 (3) 16 (5) 4 1 82 (23) 33 (9) 1
Leukopenia 40 (22) 5 (3) 0 59 (33) 10 (6) 0 11 (3) 0 0 38 (11) 4 (1) 0
WBC count decreased 24 (13) 1 (< 1) 0 52 (29) 4 (2) 0 4 (1) 0 0 19 (5) 4 (1) 0
Leukopenia/ WBC count decreaseda 64 (34) 6 (3) 0 111 (63) 14 (8) 0 15 (4) 0 0 57 (16) 8 0
Platelet count decreased 30 (16) 5 (3) 0 62 (35) 25 (14) 5 (3) 5 (1) 0 0 38 (11) 7 (2) 1 (< 1)
Thrombocytopenia 31 (17) 8 (4) 2 (1) 81 (46) 39 (22) 12 (7) 24 (7) 0 1 (< 1) 100 (28) 23 (6) 7 (2)
Thrombocytopenia/platelet count decreaseda 61 (33) 13 (7) 2 (1) 143 (81) 64 (36) 17 (10) 29 (8) 0 1 138 (39) 30 8
Hemoglobin decreased 21 (11) 0 0 48 (27) 8 (5) 1 (< 1) 12 (3) 4 (1) 0 21 (6) 4 (1) 0
Anemia 13 (7) 1 (< 1) 3 (2) 51 (29) 10 (6) 3 (2) 24 (7) 2 (< 1) 3 (< 1) 50 (14) 11 (3) 3 (< 1)
Anemia/hemoglobin decreaseda 34 (18) 1 (< 1) 3 (2) 99 (56) 18 (10) 4 36 (10) 6 3 71 (20) 15 3
  1. aRelated AEs were pooled